A*STAR Scientists Discover "Switch" to Boost Anti-Viral Response to Fight Infectious Diseases
Published: May 11, 2012
2. While there are anti-viral drugs to treat influenza, the high rates of mutation that are characteristic of the influenza virus have made it difficult to treat with one universal drug or vaccine. As for dengue, there are currently no clinically approved vaccines or cures either. This discovery of BTK’s role as a critical ‘switch’ that boosts the body’s anti-viral response, paves the way for developing anti-viral drugs that target the BTK ‘switch’ to fight infectious diseases.
3. To investigate the role of BTK in innate immunity, the research team from BTI extracted a class of innate immune cells known as macrophages from both normal mice and from mice deficient in BTK and challenged them with the dengue virus. They found that the BTK-deficient immune cells were unable to produce interferons, and hence had much higher viral counts compared to the healthy immune cells that had high-levels of interferons to fight the virus effectively.
4. To further demonstrate the critical role of BTK in anti-viral response, the team focussed on BTK’s role in Toll-like Receptor 3 (TLR3) signaling. TLR3 is needed for cells to activate the interferon response when cells are infected by viruses. The team examined the effect of having a perpetually-“on” or -“off” BTK ‘switch’ in TLR3 signaling. They uncovered that a constitutively active or “on” BTK ‘switch’ enhanced the production of interferon, resulting in a stronger and more lasting anti-viral response with significant reduction in Dengue viral counts. In contrast, a perpetually “off” BTK ‘switch’ led to a poor anti-viral response with very low levels of inteferons produced, and little protection against Dengue virus infection.
5. Previously, scientists have always thought that BTK is important primarily in antibody production due to observations made of an inherited genetic disorder in humans called X-linked Agammaglobulinemia (XLA). These patients do not have a functional BTK ‘switch’, and are unable to produce antibodies because defects in BTK cripple maturation of B cells, a type of white blood cell that produces antibodies.
6. “We are very excited because this is the first time that the link between BTK and its critical role in the immediate anti-viral responses of the immune system, triggered in response to invading viruses like Dengue, is definitively demonstrated”, said Dr. Koon-Guan Lee, the first author of this paper.
7. Said Professor Kong-Peng Lam, Acting Executive Director of BTI and the Head of the Immunology Group that conducted the research, “This study adds new insights to the understanding of how the body’s innate immunity is triggered to create an effective immune response. It is a prime example of how better understanding in basic biological systems brings us a step closer to understanding the mechanism of human diseases, and enables us to find more effective treatment strategies to combat deadly viral diseases, which we have yet to find cures for.”
2 Dengue is globally the most common mosquito-borne infection after malaria, with an estimated 50-100 million infections occurring annually. Symptoms range from mild to incapacitating high fever, with potentially life-threatening complications. http://www.who.int/mediacentre/factsheets/fs117/en/
3 Macrophages are a type of white blood cell that circulates throughout the bloodstream, engulfing foreign agents in the body.
The research findings described in this media release can be found in the 10 April 2012 issue of Proceedings of the National Academy of Sciences (PNAS), USA under the title, " Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response ” by Koon-Guan Leea, Shengli Xua, Zi-Han Kanga, Jianxin Huoa, Mei Huangb, Dingxiang Liub, Osamu Takeuchic, Shizuo Akirac, and Kong-Peng Lama,1
aImmunology Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Republic of Singapore 138668; bSchool of Biological Sciences, Nanyang Technological University, Republic of Singapore 637551; and cWorld Premier International (WPI) Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan 1To whom correspondence should be addressed. E-mail: email@example.com.
Abstract of this article can be accessed from http://www.pnas.org/content/early/2012/03/23/1119238109.abstract
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
For media queries and clarifications, please contact:
Sarah Chang (Dr.)
Agency for Science, Technology and Research
Tel: (65) 6826 6442
About the Bioprocessing Technology Institute (BTI)
Bioprocessing Technology Institute (BTI) is a member of the Agency for Science, Technology and Research (A*STAR). Established in 1990 as the Bioprocessing Technology Unit, it was renamed the Bioprocessing Technology Institute (BTI) in 2003. The research institute’s mission is to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocessing community. Someof the key research areas include expression engineering, animal cell technology, stem cell research, microbial fermentation, downstream purification and analytics.
For more information about BTI, please visit www.bti.a-star.edu.sg
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences and physical sciences and engineering research institutes, and six consortia & centres, located in Biopolis and Fusionopolis as well as their immediate vicinity.
A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, and with other local and international partners.
For more information about A*STAR, please visit www.a-star.edu.sg.